B.S. Bhati: Cracking the Brain Barrier – Lazertinib vs Osimertinib in EGFR+ NSCLC
B.S. Bhati, Medical Oncologist at AIIMS New Delhi, shared a post on X about a paper by James CH Yang et al. published in Clinical Lung Cancer:
“Cracking the Brain Barrier: Lazertinib vs Osimertinib in EGFR+ NSCLC
CNS Outcomes in EGFR+ NSCLC
Lazertinib (LASER201/301):
- iORR 92%
- iPFS 27.7 mo
- iDoR 26.5 mo
Osimertinib (FLAURA):
- iORR 91% vs 68%
- iPFS NR vs 13.9 mo (HR 0.48)
- iDoR ~15.2 mo
Osimertinib+Chemo (FLAURA2):
- iORR ~89% vs ~82%
- 12-mo CNS PFS 89% vs 82%
- DCR >95%
Both lazertinib and osimertinib show strong CNS efficacy
FLAURA2 combo maintains CNS protection and boosts systemic PFS.”
Title: Central nervous system outcomes of lazertinib treatment in EGFR-mutated advanced NSCLC: Pooled analysis from LASER201 and LASER301
Authors: James CH Yang, Myung-Ju Ahn, Joo-Hang Kim, Yun-Gyoo Lee, Ji-Youn Han, Ki Hyeong Lee, Anastasia Zimina, Dong-Wan Kim, Kyung-Hee Lee, Sung Sook Lee, Chun Sen Lim, Yueh Ni Lim, Young Joo Min, Sergey Orlov, Youngjoo Lee, YuKyung Kim, Mi-Jung Kwon, Hana Lee, Hyeonchae Cho, Byoung Chul Cho
You can read the Full Article in Clinical Lung Cancer.
More posts about Lung Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023